La chaîne d'options affiche les données clés des options sur actions de CASI Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Stock, Chaîne d'Options

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

Casio Computer Co Ltd

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

News

Press Releases

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

Loop Industries (NASDAQ: LOOP) Ignites Paradigm Shift – Twist™ A Breakthrough in Circular Sustainability – More Stocks Inside

Events

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Earnings

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Penny Stocks

CASI Pharmaceuticals Appoints James Huang to Board of Directors

BTBD

CASI

LOOP

OPEN

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Boundless Bio

enGene Holdings

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Kairos Pharma

Lunai Bioworks

Leap Therapeutics

Moleculin Biotech

MetaVia

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

NextCure

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Rallybio

Rein Therapeutics

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Tharimmune

Exicure

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Options

CASI Pharmaceuticals (NASDAQ:CASI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL